EMA news in brief

Published: 22-May-2012
Regulatory


The European Medicines Agency (EMA) has released a guideline on quality, non-clinical and clinical aspects of manufacturing medicinal products containing genetically modified cells.

The agency has released some post-authorisation procedural advice for manufacturers using its centralised market approval procedure.

And EMA has published new controlled vocabularies for submitting information on medicines.

See more

You may also like

Manufacturing
Boehringer Ingelheim standardises plant maintenance globally with osapiens

Boehringer Ingelheim standardises plant maintenance globally with osapiens

Read more
Boehringer Ingelheim has selected the osapiens HUB for Mobile Maintenance for its global, regulated manufacturing operations

Trending Articles

  1. Nicox’s NCX 470 new drug application submitted in the United States by Kowa The submission is based on positive results from two Phase III clinical trials (Mont Blanc and Denali)
  2. Sanofi offers EU commitments for flu vaccine disparagement claims Sanofi has proposed remedies to EU antitrust regulators after allegations it disparaged rival CSL Seqirus's Fluad vaccine in Germany and France since 2024
  3. FINAT Recognises Digital Security Seal from Schreiner MediPharm Schreiner MediPharm, a leading developer and manufacturer of innovative functional labels for the healthcare industry, received the prestigious Group Award for Innovation for a newly developed security seal with an integrated digital authentication function in the FINAT Label Competition 2026
  4. NSF Founded in 1944, NSF’s mission is to protect and improve global human health. NSF, Pharmaceutical Services provides a comprehensive range of independent, third-party pharmaceutical and biotech support services for the pharmaceutical industry. These services are delivered by some of the most knowledgeable experts in their fields. Whether you’re looking for pharmaceutical consulting, training, auditing or regulatory guidance, you can trust the experts at NSF.
  5. ATEX zones explained: classifying hazardous areas in chemical manufacturing When a dust explosion killed six workers at a US pharmaceutical plant in 2003, the hazard was on file. What was missing was area classification, the foundation of every ATEX decision that follows

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Manufacturing
Boehringer Ingelheim standardises plant maintenance globally with osapiens

Boehringer Ingelheim standardises plant maintenance globally with osapiens

Boehringer Ingelheim has selected the osapiens HUB for Mobile Maintenance for its global, regulated manufacturing operations
Manufacturing
Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

With throughput up to 100 kg/h, the new twin-screw extruder brings lab-grade process understanding into pilot-scale production, enabling users to validate process parameters and produce relevant quantities under realistic conditions
Regulatory
Sanofi offers EU commitments for flu vaccine disparagement claims

Sanofi offers EU commitments for flu vaccine disparagement claims

Sanofi has proposed remedies to EU antitrust regulators after allegations it disparaged rival CSL Seqirus's Fluad vaccine in Germany and France since 2024
Manufacturing
ATEX zones explained: classifying hazardous areas in chemical manufacturing

ATEX zones explained: classifying hazardous areas in chemical manufacturing

When a dust explosion killed six workers at a US pharmaceutical plant in 2003, the hazard was on file. What was missing was area classification, the foundation of every ATEX decision that follows
Manufacturing
Watlow launches Edge Process Management platform for trusted process records in regulated industries

Watlow launches Edge Process Management platform for trusted process records in regulated industries

The platform is designed as a modular, distributed platform that unifies data, control and automation in a single architecture, enabling manufacturers to move beyond fragmented systems and legacy chart recorders towards a consistent approach to process management across assets, sites and regulatory environments
Regulatory
Nicox’s NCX 470 new drug application submitted in the United States by Kowa

Nicox’s NCX 470 new drug application submitted in the United States by Kowa

The submission is based on positive results from two Phase III clinical trials (Mont Blanc and Denali)
Regulatory
Why SLTs fail on the PQS/QMS: The leadership gap undermining quality

Why SLTs fail on the PQS/QMS: The leadership gap undermining quality

Senior leadership teams hold the ultimate responsibility for an effective Pharmaceutical Quality System. Yet across the industry, PQS failures remain one of the most consistent findings in regulatory inspections. Why?
Subscribe now